Thèse de doctorat : Sciences et techniques de l'environnement : Paris 12 : 2005. / Version électronique uniquement consultable au sein de l'Université Paris 12 (Intranet). Titre provenant de l'écran-titre. Bibliogr. : 227 réf.

Diss. (sammanfattning) Stockholm : Karol. inst., 2002. / Härtill 4 uppsatser.

Diss. (sammanfattning) Stockholm : Karol. inst., 2004. / Härtill 4 uppsatser.

Diss. (sammanfattning) Stockholm : Karol. inst., 2004. / Härtill 4 uppsatser.

Thesis (M.S.)--University of Southern California, 1999. / eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references.

Thesis (doctoral)--University of Göteborg, 1983. / Extra t.p. with thesis statement inserted. Includes the author's five published papers. Includes bibliographical references.

Thesis (doctoral)--University of Göteborg, 1983. / Extra t.p. with thesis statement inserted. Includes the author's five published papers. Includes bibliographical references.

A neutral calcium-activated protease of muscle (CAP) has previously been characterised and may play a role in myofibrillar disassembly and turnover. In this study both CAP and endogenous CAP inhibitor from adult and embryonic chicken skeletal muscle have been partially purified by DEAE-cellulose and Sephadex G-150 chromatography. CAP from embryonic muscle shows similar properties to the corresponding enzyme from adult tissue with respect to calcium dependence (maximum activity at 1.0 rnM Ca²⁺), pH optimum (7.2) and sensitivity to proteinase inhibitors (inhibited by leupeptin and chymostatin). Both embryonic and adult enzymes were found to have molecular weights of 112000 daltons by gel filtration on Sephadex G-150. CAP activity was present in cultured skeletal muscle cells and increased with cellular growth and differentiation (five-fold). The presence of an inhibitor of CAP was demonstrated in cell cultures by ion-exchange chromatography, the levels of which decreased with a simultaneous increase in CAP activity. CAP activity showed an increase in developing muscle from 12-day embryos to 7-week chicks in relation to cellular DNA (3.8- fold), although the extent of this increase did not match the extent of accumulation of myofibrillar proteins. High levels of CAP inhibitor were found in early embryonic muscle and these decreased markedly during development. CAP inhibitor from embryonic tissue was fractionated into 3 species using DEAE-cellulose in contrast to inhibitor from adult tissue which exhibited only two species. The results indicate that the levels of CAP greatly increase at a time when myofibrillar content of muscle is rapidly increasing and, in addition, demonstrate that CAP activity may be controlled to a large extent by the levels of an intracellular inhibitor.

No description available.

Introduction : La protéase High Temperature Requirement Factor A1 (HtrA1) pourrait être associée au pronostic du cancer de l’ovaire (CO). Objectif : Évaluer l’effet de l’expression de HtrA1 dans des tissus tumoraux sur le pronostic des femmes avec un CO séreux. Méthodes : Une étude de cohorte a été menée chez 122 femmes ayant un CO séreux traitées au CHU de Québec entre 1993-2006. Par immunohistochimie, l’expression de HtrA1 a été mesurée de façon visuelle et informatisée (% noyaux positifs). Des risques relatifs (HR) de progression et de décès ont été estimés avec le modèle de Cox multivarié. Résultats: Un faible pourcentage de noyaux marqués par HtrA1 était associé à une diminution des risques de progression (visuel HR=0,66, p=0,04, informatique HR=0,63, p=0,03) et de décès (visuel HR=0,69, p=0,09, informatique HR=0,56, p=0,01). Conclusion : La sous-expression de HtrA1 était associée à un meilleur pronostic des femmes avec un CO séreux. / Background: The protease High Temperature Requirement Factor A1 (HtrA1) might be associated with prognosis in ovarian cancer (OC). Objective: To evaluate the effect of HtrA1 expression in tumoral tissues on prognosis of women with serous OC. Methods: A cohort study was conducted among 122 women with a serous OC treated at the CHU de Québec between 1993-2006. Tissue microarrays were immunostained for HtrA1. HtrA1 expression was assessed visually and by digital image analysis (% of positive nuclei). Cox regression multivariate models taking into account standard prognostic factors were used to estimate adjusted hazard ratios (HR) of progression and death. Results: Low percentage of HtrA1 marked nuclei was associated with lower risks of progression (visual HR=0.66, p=0.04, digital HR=0.63, p=0.03) and death (visual HR=0.69, p=0.09, digital HR=0.56, p=0.01). Conclusion: Nuclear downregulation of HtrA1 was associated with a better prognosis in women with serous OC.